---
document_datetime: 2025-12-02 05:25:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/orserdu.html
document_name: orserdu.html
version: success
processing_time: 0.1182177
conversion_datetime: 2025-12-25 05:53:43.259992
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Orserdu

[RSS](/en/individual-human-medicine.xml/67718)

##### Authorised

This medicine is authorised for use in the European Union

elacestrant Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Orserdu](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80179)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Orserdu is a cancer medicine used to treat postmenopausal women and men with breast cancer that is locally advanced or metastatic (has spread to other parts of the body).

Orserdu can only be used when the cancer cells have receptors (targets) for the hormone oestrogen on their surface (oestrogen receptor-positive; ER-positive) and do not have large quantities of a receptor for human epidermal growth factor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called ESR1. Orserdu is used in patients whose cancer has not responded to or has progressed further following at least one hormone treatment, including a medicine belonging to the class of CDK 4/6 inhibitors.

Orserdu contains the active substance elacestrant.

Expand section

Collapse section

## How is Orserdu used?

Orserdu can only be obtained with a prescription and treatment should be started by a doctor experienced in the use of cancer medicines.

Orserdu is available as tablets to be taken by mouth once a day. Treatment should continue for as long as the patient benefits from it or side effects become unmanageable.

For more information about using Orserdu, see the package leaflet or contact your doctor or pharmacist.

## How does Orserdu work?

ER-positive breast cancer is stimulated to grow when the hormone oestrogen attaches to receptors on cancer cells. The active substance in Orserdu, elacestrant, blocks and destroys these receptors; as a result, oestrogen no longer stimulates these cancer cells to grow and this slows down the growth of the cancer.

## What benefits of Orserdu have been shown in studies?

Orserdu was investigated in one main study involving 478 patients with ER-positive, HER2-negative breast cancer that had started to spread, and whose cancer had come back or did not respond to at least one previous treatment. The study showed that, among patients whose cancer cells had an ESR1 mutation, those treated with Orserdu lived on average for 3.8 months without their disease getting worse, compared with 1.9 months for patients who received standard therapy.

## What are the risks associated with Orserdu?

For the full list of side effects and restrictions with Orserdu, see the package leaflet.

The most common side effects with Orserdu (which may affect more than 1 in 10 people) include nausea (feeling sick), decreased appetite, increased levels of fats and cholesterol in the blood, vomiting, tiredness, dyspepsia (indigestion), diarrhoea, back pain, joint pain, constipation, headache, hot flush, abdominal (belly) pain, anaemia (low levels of red blood cells), increased blood levels of alanine and aspartate aminotransferase (a sign of liver problems) or creatinine (a sign of kidney problems), and decreased blood levels of calcium, sodium and potassium.

## Why is Orserdu authorised in the EU?

Orserdu was shown to be effective at increasing the time before the disease got worse in patients with ER-positive and HER2-negative breast cancer that is advanced or has spread and who have an ESR1 mutation. Orserdu's safety is in line with other medicines of the same class and its side effects are considered manageable. The European Medicines Agency therefore decided that Orserdu's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Orserdu?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Orserdu have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Orserdu are continuously monitored. Suspected side effects reported with Orserdu are carefully evaluated and any necessary action taken to protect patients.

## Other information about Orserdu

Orserdu received a marketing authorisation valid throughout the EU on 15 September 2023.

Orserdu : EPAR - Medicine overview

Reference Number: EMA/342493/2023

English (EN) (119.34 KB - PDF)

**First published:** 09/10/2023

[View](/en/documents/overview/orserdu-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-341)

български (BG) (151.47 KB - PDF)

**First published:**

09/10/2023

[View](/bg/documents/overview/orserdu-epar-medicine-overview_bg.pdf)

español (ES) (119.39 KB - PDF)

**First published:**

09/10/2023

[View](/es/documents/overview/orserdu-epar-medicine-overview_es.pdf)

čeština (CS) (141.65 KB - PDF)

**First published:**

09/10/2023

[View](/cs/documents/overview/orserdu-epar-medicine-overview_cs.pdf)

dansk (DA) (118.54 KB - PDF)

**First published:**

09/10/2023

[View](/da/documents/overview/orserdu-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.95 KB - PDF)

**First published:**

09/10/2023

[View](/de/documents/overview/orserdu-epar-medicine-overview_de.pdf)

eesti keel (ET) (122.21 KB - PDF)

**First published:**

09/10/2023

[View](/et/documents/overview/orserdu-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.05 KB - PDF)

**First published:**

09/10/2023

[View](/el/documents/overview/orserdu-epar-medicine-overview_el.pdf)

français (FR) (120.22 KB - PDF)

**First published:**

09/10/2023

[View](/fr/documents/overview/orserdu-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.28 KB - PDF)

**First published:**

09/10/2023

[View](/hr/documents/overview/orserdu-epar-medicine-overview_hr.pdf)

italiano (IT) (118.21 KB - PDF)

**First published:**

09/10/2023

[View](/it/documents/overview/orserdu-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (148.71 KB - PDF)

**First published:**

09/10/2023

[View](/lv/documents/overview/orserdu-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.76 KB - PDF)

**First published:**

09/10/2023

[View](/lt/documents/overview/orserdu-epar-medicine-overview_lt.pdf)

magyar (HU) (139.51 KB - PDF)

**First published:**

09/10/2023

[View](/hu/documents/overview/orserdu-epar-medicine-overview_hu.pdf)

Malti (MT) (143.12 KB - PDF)

**First published:**

09/10/2023

[View](/mt/documents/overview/orserdu-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.35 KB - PDF)

**First published:**

09/10/2023

[View](/nl/documents/overview/orserdu-epar-medicine-overview_nl.pdf)

polski (PL) (143.47 KB - PDF)

**First published:**

09/10/2023

[View](/pl/documents/overview/orserdu-epar-medicine-overview_pl.pdf)

português (PT) (119.83 KB - PDF)

**First published:**

09/10/2023

[View](/pt/documents/overview/orserdu-epar-medicine-overview_pt.pdf)

română (RO) (138.78 KB - PDF)

**First published:**

09/10/2023

[View](/ro/documents/overview/orserdu-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.2 KB - PDF)

**First published:**

09/10/2023

[View](/sk/documents/overview/orserdu-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.81 KB - PDF)

**First published:**

09/10/2023

[View](/sl/documents/overview/orserdu-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.86 KB - PDF)

**First published:**

09/10/2023

[View](/fi/documents/overview/orserdu-epar-medicine-overview_fi.pdf)

svenska (SV) (117.71 KB - PDF)

**First published:**

09/10/2023

[View](/sv/documents/overview/orserdu-epar-medicine-overview_sv.pdf)

Orserdu : EPAR - Risk management plan

English (EN) (596.29 KB - PDF)

**First published:** 09/10/2023

[View](/en/documents/rmp/orserdu-epar-risk-management-plan_en.pdf)

## Product information

Orserdu : EPAR - Product information

English (EN) (482.02 KB - PDF)

**First published:** 27/11/2023

**Last updated:** 14/10/2025

[View](/en/documents/product-information/orserdu-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-737)

български (BG) (554.42 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/bg/documents/product-information/orserdu-epar-product-information_bg.pdf)

español (ES) (447.14 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/es/documents/product-information/orserdu-epar-product-information_es.pdf)

čeština (CS) (503.29 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/cs/documents/product-information/orserdu-epar-product-information_cs.pdf)

dansk (DA) (468.79 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/da/documents/product-information/orserdu-epar-product-information_da.pdf)

Deutsch (DE) (443.55 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/de/documents/product-information/orserdu-epar-product-information_de.pdf)

eesti keel (ET) (440.57 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/et/documents/product-information/orserdu-epar-product-information_et.pdf)

ελληνικά (EL) (570.22 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/el/documents/product-information/orserdu-epar-product-information_el.pdf)

français (FR) (448.31 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/fr/documents/product-information/orserdu-epar-product-information_fr.pdf)

hrvatski (HR) (499.31 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/hr/documents/product-information/orserdu-epar-product-information_hr.pdf)

íslenska (IS) (450.35 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/is/documents/product-information/orserdu-epar-product-information_is.pdf)

italiano (IT) (436.22 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/it/documents/product-information/orserdu-epar-product-information_it.pdf)

latviešu valoda (LV) (486.36 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/lv/documents/product-information/orserdu-epar-product-information_lv.pdf)

lietuvių kalba (LT) (501.57 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/lt/documents/product-information/orserdu-epar-product-information_lt.pdf)

magyar (HU) (524.52 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/hu/documents/product-information/orserdu-epar-product-information_hu.pdf)

Malti (MT) (512.54 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/mt/documents/product-information/orserdu-epar-product-information_mt.pdf)

Nederlands (NL) (482.71 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/nl/documents/product-information/orserdu-epar-product-information_nl.pdf)

norsk (NO) (432.95 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/no/documents/product-information/orserdu-epar-product-information_no.pdf)

polski (PL) (518.49 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/pl/documents/product-information/orserdu-epar-product-information_pl.pdf)

português (PT) (464.44 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/pt/documents/product-information/orserdu-epar-product-information_pt.pdf)

română (RO) (493.53 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/ro/documents/product-information/orserdu-epar-product-information_ro.pdf)

slovenčina (SK) (516.34 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/sk/documents/product-information/orserdu-epar-product-information_sk.pdf)

slovenščina (SL) (503.95 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/sl/documents/product-information/orserdu-epar-product-information_sl.pdf)

Suomi (FI) (443.38 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/fi/documents/product-information/orserdu-epar-product-information_fi.pdf)

svenska (SV) (442.52 KB - PDF)

**First published:**

27/11/2023

**Last updated:**

14/10/2025

[View](/sv/documents/product-information/orserdu-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000304207 13/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Orserdu : EPAR - All authorised presentations

English (EN) (46.33 KB - PDF)

**First published:** 27/11/2023

[View](/en/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-63)

български (BG) (62.73 KB - PDF)

**First published:**

27/11/2023

[View](/bg/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.62 KB - PDF)

**First published:**

27/11/2023

[View](/es/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.88 KB - PDF)

**First published:**

27/11/2023

[View](/cs/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (47.16 KB - PDF)

**First published:**

27/11/2023

[View](/da/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.75 KB - PDF)

**First published:**

27/11/2023

[View](/de/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.47 KB - PDF)

**First published:**

27/11/2023

[View](/et/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.9 KB - PDF)

**First published:**

27/11/2023

[View](/el/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_el.pdf)

français (FR) (47.02 KB - PDF)

**First published:**

27/11/2023

[View](/fr/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (63.56 KB - PDF)

**First published:**

27/11/2023

[View](/hr/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.57 KB - PDF)

**First published:**

27/11/2023

[View](/is/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.28 KB - PDF)

**First published:**

27/11/2023

[View](/it/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.02 KB - PDF)

**First published:**

27/11/2023

[View](/lv/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.1 KB - PDF)

**First published:**

27/11/2023

[View](/lt/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (55 KB - PDF)

**First published:**

27/11/2023

[View](/hu/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.91 KB - PDF)

**First published:**

27/11/2023

[View](/mt/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.97 KB - PDF)

**First published:**

27/11/2023

[View](/nl/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.87 KB - PDF)

**First published:**

27/11/2023

[View](/no/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_no.pdf)

polski (PL) (77.09 KB - PDF)

**First published:**

27/11/2023

[View](/pl/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.9 KB - PDF)

**First published:**

27/11/2023

[View](/pt/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.27 KB - PDF)

**First published:**

27/11/2023

[View](/ro/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (63.45 KB - PDF)

**First published:**

27/11/2023

[View](/sk/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (62.57 KB - PDF)

**First published:**

27/11/2023

[View](/sl/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.97 KB - PDF)

**First published:**

27/11/2023

[View](/fi/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.11 KB - PDF)

**First published:**

27/11/2023

[View](/sv/documents/all-authorised-presentations/orserdu-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Orserdu Active substance elacestrant International non-proprietary name (INN) or common name elacestrant Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L02BA

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.

## Authorisation details

EMA product number EMEA/H/C/005898

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Stemline Therapeutics B.V.

Basisweg 10

Opinion adopted 20/07/2023 Marketing authorisation issued 15/09/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Orserdu : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (324.22 KB - PDF)

**First published:** 14/10/2025

[View](/en/documents/procedural-steps-after/orserdu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Orserdu : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (139.77 KB - PDF)

**First published:** 14/02/2024

**Last updated:** 14/10/2025

[View](/en/documents/procedural-steps-after/orserdu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Orserdu : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/358130/2023

English (EN) (6.3 MB - PDF)

**First published:** 09/10/2023

[View](/en/documents/assessment-report/orserdu-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Orserdu

Adopted

Reference Number: EMA/CHMP/325146/2023

English (EN) (162.05 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-orserdu_en.pdf)

#### News on Orserdu

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Orserdu : EPAR - Product information - tracked changes

English (EN) (203.24 KB - DOCX)

**First published:** 14/10/2025

[View](/en/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-36)

български (BG) (241.66 KB - DOCX)

**First published:**

14/10/2025

[View](/bg/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_bg.docx)

español (ES) (259.87 KB - DOCX)

**First published:**

14/10/2025

[View](/es/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_es.docx)

čeština (CS) (261.3 KB - DOCX)

**First published:**

14/10/2025

[View](/cs/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (260.36 KB - DOCX)

**First published:**

14/10/2025

[View](/da/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (258.66 KB - DOCX)

**First published:**

14/10/2025

[View](/de/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (257.12 KB - DOCX)

**First published:**

14/10/2025

[View](/et/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (223.33 KB - DOCX)

**First published:**

14/10/2025

[View](/el/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_el.docx)

français (FR) (280.04 KB - DOCX)

**First published:**

14/10/2025

[View](/fr/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (261.11 KB - DOCX)

**First published:**

14/10/2025

[View](/hr/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (260.56 KB - DOCX)

**First published:**

14/10/2025

[View](/is/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_is.docx)

italiano (IT) (283.05 KB - DOCX)

**First published:**

14/10/2025

[View](/it/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (258.62 KB - DOCX)

**First published:**

14/10/2025

[View](/lv/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (259.38 KB - DOCX)

**First published:**

14/10/2025

[View](/lt/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (265.38 KB - DOCX)

**First published:**

14/10/2025

[View](/hu/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (258.86 KB - DOCX)

**First published:**

14/10/2025

[View](/mt/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (209.45 KB - DOCX)

**First published:**

14/10/2025

[View](/nl/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (254.19 KB - DOCX)

**First published:**

14/10/2025

[View](/no/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_no.docx)

polski (PL) (261.93 KB - DOCX)

**First published:**

14/10/2025

[View](/pl/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_pl.docx)

português (PT) (206.65 KB - DOCX)

**First published:**

14/10/2025

[View](/pt/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_pt.docx)

română (RO) (258.81 KB - DOCX)

**First published:**

14/10/2025

[View](/ro/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (273.75 KB - DOCX)

**First published:**

14/10/2025

[View](/sk/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (253.16 KB - DOCX)

**First published:**

14/10/2025

[View](/sl/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (172.46 KB - DOCX)

**First published:**

14/10/2025

[View](/fi/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (250.16 KB - DOCX)

**First published:**

14/10/2025

[View](/sv/documents/product-information-tracked-changes/orserdu-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 14/10/2025

## Share this page

[Back to top](#main-content)